Yondelis (Trabectedin) Patent Expiration, LOE Window & CMS Spending
Yondelis (Trabectedin) by Johnson & Johnson: FDA Orange Book LOE 2028-07-07, 0 AB generics, $3.8M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Johnson & Johnson |
| FDA Application & Pathway | N207953 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2028-07-07 |
| Orange Book Patents (*PED Extensions) | 2 patents (1 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $3.8M |
| 2024 Medicare Part D Spend | $355K |
| 2024 Medicaid Spend | $3.5M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 22.5% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.